Dianthus Therapeutics, Inc. /DE/
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
DNTH$88.81-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(97,905) | $(56,529) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 84 | 70 |
| Stock-based compensation expense | 16,815 | 8,976 |
| Accretion of discount on investment securities | (5,308) | (3,281) |
| Amortization of right-of-use operating lease assets | 247 | 264 |
| Gain on investment in former related party | (254) | (307) |
| Changes in operating assets and liabilities: | ||
| Receivable from former related party | 807 | (1,096) |
| Unbilled receivable from former related party | — | (1,109) |
| Accounts receivable, net | (5,000) | — |
| Prepaid expenses and other current assets | (1,356) | (428) |
| Other assets | 565 | (3,111) |
| Accounts payable, accrued expenses and operating lease liabilities | 4,593 | 5,911 |
| Deferred revenue | 4,635 | — |
| Deferred revenue - former related party | — | (96) |
| Net cash used in operating activities | (82,077) | (50,736) |
| Cash flows from investing activities: | ||
| Capital expenditures | (75) | (74) |
| Purchases of investment securities | (380,278) | (305,628) |
| Proceeds from maturities of investment securities | 220,317 | 42,000 |
| Net cash used in investing activities | (160,036) | (263,702) |
| Cash flows from financing activities: | ||
| Proceeds from public offering | 272,268 | — |
| Payment of issuance costs in connection with public offering | (172) | — |
| Proceeds from exercise of stock options | 2,829 | 614 |
| Proceeds from issuance of common stock under ESPP | 316 | — |
| Proceeds from exercise of pre-funded warrants | 1 | — |
| Proceeds from private placement | — | 229,998 |
| Payment of issuance costs in connection with private placement | — | (14,665) |
| Net cash provided by financing activities | 275,242 | 215,947 |
| Increase/(decrease) in cash, cash equivalents and restricted cash | 33,129 | (98,491) |
| Cash, cash equivalents and restricted cash, beginning of period | 23,022 | 132,391 |
| Cash, cash equivalents and restricted cash, end of period | $56,151 | $33,900 |
| Supplemental Disclosure | ||
| Cash and cash equivalents | $55,984 | $33,671 |
| Restricted cash | 167 | 229 |
| Total cash, cash equivalents and restricted cash | $56,151 | $33,900 |
| Issuance costs in connection with public offering included in accounts payable | $192 | $— |
| Issuance costs in connection with public offering included in accrued expenses | $40 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.